Ekaterina Vert-Wong is a dedicated medical innovator committed to bringing high-impact vaccines to patients in need via ethical and equitable research pathways. She joined the Sabin Vaccine Institute in 2021 and leads operational, organizational and alliance management functions. She focuses on overseeing R&D programs planning and execution. She also leads the development teams in the implementation of efficient operations and cost-effective systems to meet current and future needs of the organization. Ekaterina fosters Sabin’s internal and external collaborations to move vaccine development milestones forward, secure funding, and implement long-term pipeline strategies, internally and externally via effective alliance management.
Ekaterina brings excellent knowledge of global vaccines R&D practices, proven record of success in leading medical innovation, including execution of all clinical phases and design of global regulatory strategies. Prior to joining Sabin, Ekaterina led departments within innovative and dynamic research organizations, focusing on the development and testing of vaccines and biologics. Her two decades of experience in product development includes development and licensure of BioThrax® for post-exposure prophylaxis and pre-exposure use in special populations at Emergent BioSolutions. At Synthetic Biologics, she managed development of anti-pertussis antibodies for passive vaccination applications under an alliance with the Gates Foundation that she created.
Ekaterina holds a graduate degree in management from Dartmouth College and a graduate degree in biochemistry from the Weizmann Institute of Science in Israel.
Make vaccines more accessible, enable innovation and expand immunization across the globe.